Pharm-Olam is now Allucent. Learn More
Pharm-Olam’s therapeutic areas of focus have been built to provide an ecosystem of cross-functional, therapeutically-aligned teams. This strategy helps create synergies and efficiencies that ensure your rescue study or trial optimization solutions are optimally positioned to help your clinical trial reach its goals and milestones.
Our dedicated team of cancer researchers create solutions and provide consulting focused on the needs of your sites and patients – and can bring your study back on track.
Our dedicated staff for infectious disease and vaccine research can support your current sites and tap into our global network to bring your study back on track leveraging our vast expertise from immunizations to immunotherapy.
With more than 100 rare and orphan disease clinical trials completed, we have deep expertise in rare and are prepared to meet the unique challenges of these studies.
We understand that allergy clinical trials and asthma clinical studies require present a variety of unique challenges that our Allergy CRO team is well-equipped to handle.
Pharm-Olam has the expertise, investigator relationships, and supportive technology to effectively deliver autoimmune clinical research studies.
When issues like delayed enrollment, postponed timelines, budget problems, regulatory issues, and resource constraints threaten to derail your research, Pharm-Olam’s rescue services can help get your study back on track.
Our rescue study services team can quickly analyze your study’s needs and design customized solutions to get your clinical trial moving in the right direction.
Your official transition plan will be initiated by experts from specialized areas who work in parallel to execute regulatory approvals, site agreements, and logistical requirements. They also work to build productive relationships that better position your clinical trial for success in the future, setting your study on a course for continued success.
Whether you need additional sites in an active country, sites in new countries, or want to transfer an ongoing study, we can help you meet your enrollment needs. Since slow recruitment is the number one clinical trial issue, we have a rescue startup team that analyzes your enrollment options rapidly. We also provide you with a global network and decentralized monitoring model that allows us to quickly initiate sites in countries with higher recruitment rates than the U.S. or Western Europe.
Our proven processes and solutions are designed to improve communication between all teams to alleviate future study issues before they arise and put your clinical study on the road to success.
Are you looking for assistance on how to plan and execute a rescue scenario? Watch our on-demand webinar - Rescue Your Study: A Sponsor’s Playbook.
Healthcare-associated infections (HAIs), also referred to as “nosocomial” or “hospital” infections,...
“Adaptive designs” in clinical research refer to study designs where certain features are left...
The ongoing COVID-19 pandemic has brought into focus the impact that respiratory viral infections...
